Patents by Inventor Gavin Barry Wild

Gavin Barry Wild has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11834514
    Abstract: The present invention provides method for increasing the percentage of monomer in a composition of recombinantly expressed antibody molecules characterised in that the antibody molecule comprises at least one Fv with specificity for an antigen of interest comprising one VH and one VL wherein said VH and VL are connected directly or indirectly via one or more linkers and are stabilised by a disulfide bond therebetween, said method comprises a) a thermal conversion step of holding the composition comprising the antibody molecule at a temperature in the range 30 to 60° C. for a period of at least 1 hour, wherein step a) is performed in the presence of a reducing agent or after treatment with a reducing agent.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: December 5, 2023
    Assignee: UCB BIOPHARMA SRL
    Inventors: Sam Philip Heywood, Gavin Barry Wild, Christopher John Le Page, Razwan Hanif
  • Patent number: 11786593
    Abstract: The present invention provides method of increasing the percentage of monomer in a composition of recombinantly expressed antibody molecules characterised in that the antibody molecule comprises at least one Fv with specificity for an antigen of interest comprising one VH and one VL wherein said VH and VL are connected directly or indirectly via one or more linkers and are stabilised by a disulfide bond therebetween, said method comprises: a) a conversion step of treating the composition with a denaturant selected from urea and/or Guanidine hydrochloride; b) wherein step a) is performed in the presence of a reducing agent or after treatment with a reducing agent.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: October 17, 2023
    Assignee: UCB BIOPHARMA SRL
    Inventors: Sam Philip Heywood, Gavin Barry Wild, Razwan Hanif, Christopher John Le Page
  • Publication number: 20210171609
    Abstract: The present invention provides a method for recovering a human VH3 domain-containing antibody in monomeric form. In particular the present invention provides a new method that allows recovery of monomeric human VH3 domain-containing antibodies from a mixture containing monomeric and multimeric forms of the antibody.
    Type: Application
    Filed: February 17, 2021
    Publication date: June 10, 2021
    Inventors: SAM PHILIP HEYWOOD, GAVIN BARRY WILD
  • Publication number: 20210079120
    Abstract: The present invention provides method for increasing the percentage of monomer in a composition of recombinantly expressed antibody molecules characterised in that the antibody molecule comprises at least one Fv with specificity for an antigen of interest comprising one VH and one VL wherein said VH and VL are connected directly or indirectly via one or more linkers and are stabilised by a disulfide bond therebetween, said method comprises a) a thermal conversion step of holding the composition comprising the antibody molecule at a temperature in the range 30 to 60° C. for a period of at least 1 hour, wherein step a) is performed in the presence of a reducing agent or after treatment with a reducing agent.
    Type: Application
    Filed: October 23, 2020
    Publication date: March 18, 2021
    Inventors: SAM PHILIP HEYWOOD, GAVIN BARRY WILD, CHRISTOPHER JOHN LE PAGE, RAZWAN HANIF
  • Publication number: 20210069328
    Abstract: The present invention provides method of increasing the percentage of monomer in a composition of recombinantly expressed antibody molecules characterised in that the antibody molecule comprises at least one Fv with specificity for an antigen of interest comprising one VH and one VL wherein said VH and VL are connected directly or indirectly via one or more linkers and are stabilised by a disulfide bond therebetween, said method comprises: a) a conversion step of treating the composition with a denaturant selected from urea and/or Guanidine hydrochloride; b) wherein step a) is performed in the presence of a reducing agent or after treatment with a reducing agent.
    Type: Application
    Filed: October 23, 2020
    Publication date: March 11, 2021
    Inventors: SAM PHILIP HEYWOOD, GAVIN BARRY WILD, RAZWAN HANIF, CHRISTOPHER JOHN LE PAGE
  • Patent number: 10927164
    Abstract: The present invention provides a method for recovering a human VH3 domain-containing antibody in monomeric form. In particular the present invention provides a new method that allows recovery of monomeric human VH3 domain-containing antibodies from a mixture containing monomeric and multimeric forms of the antibody.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: February 23, 2021
    Assignee: UCB BIOPHARMA SRL
    Inventors: Sam Philip Heywood, Gavin Barry Wild
  • Patent number: 10829565
    Abstract: The present invention provides method for increasing the percentage of monomer in a composition of recombinantly expressed antibody molecules characterised in that the antibody molecule comprises at least one Fv with specificity for an antigen of interest comprising one VH and one VL wherein said VH and VL are connected directly or indirectly via one or more linkers and are stabilised by a disulfide bond therebetween, said method comprises a) a thermal conversion step of holding the composition comprising the antibody molecule at a temperature in the range 30 to 60° C. for a period of at least 1 hour, wherein step a) is performed in the presence of a reducing agent or after treatment with a reducing agent.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: November 10, 2020
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Sam Philip Heywood, Gavin Barry Wild, Christopher John Le Page, Razwan Hanif
  • Patent number: 10828366
    Abstract: The present invention provides method of increasing the percentage of monomer in a composition of recombinantly expressed antibody molecules characterised in that the antibody molecule comprises at least one Fv with specificity for an antigen of interest comprising one VH and one VL wherein said VH and VL are connected directly or indirectly via one or more linkers and are stabilised by a disulfide bond therebetween, said method comprises: a) a conversion step of treating the composition with a denaturant selected from urea and/or Guanidine hydrochloride; b) wherein step a) is performed in the presence of a reducing agent or after treatment with a reducing agent.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: November 10, 2020
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Sam Philip Heywood, Gavin Barry Wild, Razwan Hanif, Christopher John Le Page
  • Publication number: 20180142039
    Abstract: The present invention provides method for increasing the percentage of monomer in a composition of recombinantly expressed antibody molecules characterised in that the antibody molecule comprises at least one Fv with specificity for an antigen of interest comprising one VH and one VL wherein said VH and VL are connected directly or indirectly via one or more linkers and are stabilised by a disulfide bond therebetween, said method comprises a) a thermal conversion step of holding the composition comprising the antibody molecule at a temperature in the range 30 to 60° C. for a period of at least 1 hour, wherein step a) is performed in the presence of a reducing agent or after treatment with a reducing agent.
    Type: Application
    Filed: April 22, 2016
    Publication date: May 24, 2018
    Inventors: Sam Philip HEYWOOD, Gavin Barry WILD, Christopher John LE PAGE, Razwan HANIF
  • Publication number: 20180117153
    Abstract: The present invention provides method of increasing the percentage of monomer in a composition of recombinantly expressed antibody molecules characterised in that the antibody molecule comprises at least one Fv with specificity for an antigen of interest comprising one VH and one VL wherein said VH and VL are connected directly or indirectly via one or more linkers and are stabilised by a disulfide bond therebetween, said method comprises: a) a conversion step of treating the composition with a denaturant selected from urea and/or Guanidine hydrochloride; b) wherein step a) is performed in the presence of a reducing agent or after treatment with a reducing agent.
    Type: Application
    Filed: April 22, 2016
    Publication date: May 3, 2018
    Inventors: Sam Philip HEYWOOD, Gavin Barry WILD, Razwan HANIF, Christopher John LE PAGE
  • Publication number: 20180100007
    Abstract: The present invention provides a method for recovering a human VH3 domain-containing antibody in monomeric form. In particular the present invention provides a new method that allows recovery of monomeric human VH3 domain-containing antibodies from a mixture containing monomeric and multimeric forms of the antibody.
    Type: Application
    Filed: April 20, 2016
    Publication date: April 12, 2018
    Inventors: SAM PHILIP HEYWOOD, GAVIN BARRY WILD
  • Patent number: 9751930
    Abstract: The present invention provides method for purifying a recombinant protein from a gram-negative bacterial host cell sample or extract thereof wherein said host cell expresses a recombinant protein and a recombinant disulphide isomerase DsbC; comprising: a. adjusting the pH of the host cell sample or extract thereof to a pH of 5 or less to precipitate the recombinant disulphide isomerase; and b. separating precipitated recombinant disulphide isomerase DsbC from the recombinant protein to produce a recombinant protein sample.
    Type: Grant
    Filed: July 27, 2011
    Date of Patent: September 5, 2017
    Assignee: UCB PHARMA, S.A.
    Inventor: Gavin Barry Wild
  • Publication number: 20130178607
    Abstract: The present invention provides method for purifying a recombinant protein from a gram-negative bacterial host cell sample or extract thereof wherein said host cell expresses a recombinant protein and a recombinant disulphide isomerase DsbC; comprising: a. adjusting the pH of the host cell sample or extract thereof to a pH of 5 or less to precipitate the recombinant disulphide isomerase; and b. separating precipitated recombinant disulphide isomerase DsbC from the recombinant protein to produce a recombinant protein sample.
    Type: Application
    Filed: July 27, 2011
    Publication date: July 11, 2013
    Applicant: UCB PHARMA S.A.
    Inventor: Gavin Barry Wild